SciBrunch

AboutSciBrunch

We are a clinical-stage biotech driven by iterative innovation in small molecule therapeutics. Our pipeline targets clinically validated oncology pathways, with a strategic focus on hard-to-treat malignancies such as PDAC and CRC

By synergizing deep expertise in medicinal chemistry with agile business development, we build differentiated asset portfolios dedicated to delivering novel life-saving treatments to patients worldwide

About

SciBrunch

Focus

M
Annual Incidence of RAS-Mutant PDAC and CRC Patients
Funding
$
M
From Angel and Pre-A Rounds
Pipelines
≥
1 in Phase I, 1 in IND Enabling, 2 in Discovery

Brain-penetrant PARP1 selective inhibitor

Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer

KRAS G12D（on）molecular glue

Pancreatic Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer

KRAS G12V（on）molecular glue

R&D

Pipeline

Brain-penetrant PARP1 selective inhibitor

KRAS G12D（on）molecular glue

KRAS G12V（on）molecular glue


Brain-penetrant PARP1 selective inhibitor
Breast Cancer, Glioma, Ovarian Cancer, Prostate Cancer
KRAS G12D（on）molecular glue
Pancreatic Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer
KRAS G12V（on）molecular glue

learn more



Our

Founders



Tao HU, PhD

FounderChairmanCEO

Dr. Hu brings more than 20 years of experience in drug discovery, operational management, and business development. He previously held senior executive roles at WuXi AppTec, where he oversaw a wide variety of project collaborations with over 30 multinational corporations and biotech companies. Prior to that, he conducted small-molecule drug R&D in neurology, oncology, and inflammation at Merck and Amgen in the US.

learn more





Yang ZHANG, PhD

Co-FounderCSO

Dr. Zhang is a seasoned medicinal chemist with over 20 years of experience in drug discovery. Prior to founding SciBrunch Therapeutics, he served as Vice President at WuXi AppTec's DDSU, where he successfully delivered more than 30 preclinical projects with competitive advantages to both domestic and international clients.

learn more

